menu
    • menu

    Company profile for Global Pharma Healthcare

    Global MixGIF-PSE
    News
    FDA approves Omeros' drug to treat transplant complication

    27 Dec 2025

    // REUTERS

    J&J Halts Mid-stage Trial of Experimental Eczema Drug

    27 Dec 2025

    // REUTERS

    Sanofi to acquire Dynavax, Pushes Ahead on Adult Vaccines

    27 Dec 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    VB RM

    Contact Supplier

    Website

    Arab Health

    Exhibiting

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://youtu.be/nkhBP3zhrgw?si=MMieOowEsnTtAFJk

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Related CompaniesRelated Companies

    About

    Global Pharma Healthcare, established in 1999, has nearly three decades of experience in producing APIs, finished formulations, and nutraceuticals at its EU-GMP and WHO-GMP certified facilities in Chennai. The company supports contract manufacturing from development through commercial supply. With 700+ registrations and strong regulatory capability, it supplies products to over 40 countries across Asia, Africa, CIS, Europe, and LATAM. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Global Pharma Healthcareindia-flag Flag
    Country
    Country
    India
    Address
    Address
    #2A, 3rd Floor Ganga Street 4th Cross Street Kodambakkam, Chennai, 600024
    Telephone
    Telephone
    +91 4427444408
    Client Email
    Email
    raj@global-pharma.com
    Client Website
    Website
    https://global-pharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/global-pharma-healthcare-ltd./?originalSubdomain=in
    youtube
    YouTube
    https://www.youtube.com/@globalpharma1901
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/global-pharma-healthcare-party-content-10275.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/global-pharma-healthcare-party-content-76563.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Glocare: Expanding List of International Approvals

    read-more

      https://www.pharmacompass.com/pdf/party/content/global-pharma-healthcare-party-content-59054.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/global-pharma-healthcare-party-content-87846.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Glocare Labs: Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/global-pharma-healthcare-party-content-95954.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Glocare CRO Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/global-pharma-healthcare-party-content-84340.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Pfizer’s buyout of Seagen, drugmakers suing US govt, obesity drugs make it to top 10 Phispers of 2023

    Pfizer’s buyout of Seagen, drugmakers suing US govt, obesity drugs make it to top 10 Phispers of 2023

    Every week, PharmaCompass compiles important developments in the world of pharmaceuticals and brings a compilation to you in the form of Phispers. Of the hundreds of stories we carried in 2023, here are the top 10 stories, including some trends and updates.I. Pfizer buys Seagen for US$ 43 billion to bolster its oncology portfolioIn March, Pfizer said it is acquiring cancer treatment specialist Seagen for US$ 43 billion. Seagen is a pioneer in antibody-drug conjugates (ADCs), or drugs that work like “guided missiles” to destroy cancer cells while sparing healthy cells. Another important deal in the field of ADCs took place in December when AbbVie picked up ImmunoGen for US$ 10.1 billion, giving it access to Elahere (mirvetuximab soravtansine-gynx), an ADC approved for platinum-resistant ovarian cancer. Elahere is expected to achieve blockbuster status by 2030. II. Merck, BMS, trade bodies, sue US government over IRA negotiationsIn June, Merck filed a lawsuit against the US government seeking to block Medicare from negotiating lower prescription drug prices under the Inflation Reduction Act (IRA). Days later, the US Chamber of Commerce, one of the most influential trade groups in the US, filed a separate lawsuit, arguing that the negotiations violated drugmakers’ constitutional rights and granted excessive control over prices to the government. They were joined by Bristol Myers Squibb (BMS) and lobby group PhRMA. Drugmakers and the Biden administration appeared to be at each other’s throats. In December, the White House identified 48 drugs whose prices spiked faster than inflation in Q4. These drugs may be subject to rebates starting January 2024. Biden Administration also announced it is setting a new “march-in” policy that allows the government to seize medicine patents held by drugmakers for therapies whose development was taxpayer-funded, if it believes they are not “reasonably available and affordable.”III. US, UK approve Lilly’s Mounjaro for weight management; to be sold as ZepboundIn November, drug regulators in the US and the United Kingdom approved Eli Lilly's Mounjaro (tirzepatide) for weight management, to be sold under the brand name Zepbound. The drug will pose strong competition to Novo Nordisk’s Wegovy in a market that's expected to reach US$ 100 billion by the end of the decade.IV. Novo, Lilly plan capacity expansions for weight loss drugsBoth Novo Nordisk and Eli Lilly announced expanding their manufacturing capacities in order to capitalize on the burgeoning market for weight loss drugs. Novo is investing over DKK 42 billion (US$ 6 billion) in Kalundborg (Denmark), US$ 2.3 billion to expand its site in Chartres (France) and over € 2 billion (US$ 2.18 billion) in Dublin (Ireland) to boost production of its blockbuster diabetes and weight-loss drugs, including Ozempic and Wegovy (both semaglutide). Similarly, Eli Lilly had announced a US$ 2.5 billion manufacturing facility in Germany in November to address the demand for its new obesity and diabetes therapies.V. FDA finds violations at Global Pharma’s eye drops plant in India; issues Form 483In April, FDA found several violations in manufacturing processes and sterilization methods used by India-based Global Pharma for its EzriCare Artificial Tears Eye Drop, which has been linked to 68 cases of eye infection in the US, including eight cases of vision loss and three deaths.VI. ‘Intas India staff tore documents, threw acid to destroy evidence’, notes FDAIn January, FDA issued a Form 483 with 11 observations to Intas Pharma’s drug manufacturing facility in Ahmedabad (Gujarat, India). A team of three FDA drug regulators conducted an inspection of the manufacturing facility from November 22 to December 2, 2022. The 36-page report issued by the FDA has alleged that employees at the facility had destroyed documents related to manufacturing practices by tearing them into pieces and disposing them inside the quality control lab and scrap areas. Acid was used to destroy evidence, notes FDA.VII. GSK overtakes Pfizer in bagging first FDA approval for RSV vaccineIn May, FDA approved GSK’s respiratory syncytial virus (RSV) vaccine for people aged 60 and above. Arexvy is the first RSV vaccine to be approved in the US for the common condition that can be fatal for the elderly. Later that month, Pfizer’s RSV vaccine Abrysvo also got approved. In July, Sanofi-AstraZeneca’s RSV antibody therapy, Beyfortus (nirsevimab-alip), received approval from the FDA. It is a long-acting treatment that can be given once per season. The approval is specifically developed for newborns and infants.VIII. UK authorizes gene therapy Casgevy for blood disorders, US follows suit In November, Britain’s Medicines and Healthcare products Regulatory Agency was first off the block in authorizing CRISPR Therapeutics and Vertex Pharmaceuticals’ Casgevy, a therapy that seeks to cure two blood disorders — sickle-cell disease (SCD) and β-thalassemia. The therapy is based on gene editing technology that had won its scientists the Nobel Prize in Chemistry in 2020.Less than a month later, FDA not only approved Casgevy (exagamglogene autotemcel) for SCD, but also approved bluebird bio’s Lyfgenia (lovotibeglogene autotemcel) for the treatment of SCD in patients aged 12 and older who have a history of vaso-occlusive events (when tissues become deprived of oxygen).IX. Leqembi becomes first med to bag full approval to treat Alzheimer’sEisai and Biogen’s Alzheimer’s drug Leqembi (lecanemab) had won FDA’s accelerated approval in January. It treats patients who are in the earliest stages of the neurodegenerative disease. In July, it became the first treatment to receive full FDA approval to treat the condition.X. Bayer’s experimental anticoagulant fails late-stage trialOne of the biggest disappointments from clinical trials came when a major late-stage trial for Bayer’s experimental anticoagulant asundexian had to be discontinued due to its inadequate effectiveness. Bayer had expectations in excess of € 5 billion (US$ 5.5 billion) from this drug.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3194

    https://www.pharmacompass.com/radio-compass-blog/pfizer-s-buyout-of-seagen-drugmakers-suing-us-govt-obesity-drugs-make-it-to-top-10-phispers-of-2023

    #Phispers by PHARMACOMPASS
    18 Jan 2024
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Global Pharma Healthcare and get a quotation

    Global Pharma Healthcare is a supplier offers 9 products (APIs, Excipients or Intermediates).

    Find a price of Ciprofloxacin bulk offered by Global Pharma Healthcare

    Find a price of Ciprofloxacin Hydrochloride bulk offered by Global Pharma Healthcare

    Find a price of Gatifloxacin bulk offered by Global Pharma Healthcare

    Find a price of Levofloxacin bulk offered by Global Pharma Healthcare

    Find a price of Levofloxacin Hemihydrate bulk offered by Global Pharma Healthcare

    Find a price of Moxifloxacin bulk offered by Global Pharma Healthcare

    Find a price of Moxifloxacin Hydrochloride bulk offered by Global Pharma Healthcare

    Find a price of Norfloxacin bulk offered by Global Pharma Healthcare

    Find a price of Ofloxacin bulk offered by Global Pharma Healthcare

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search